Expert Interview
A Second Look: Reviewing Avidity Biosciences Phase 1/2 FORTITUDE trial of AAOC- 1020 (del-brax) for FSHD
Ticker(s): RNA, FULC- Physician-scientist & Associate professor, Department of Neurology at major US medical center.
- Manages 20 patients with myotonic dystrophy type 1 (DM1).
- Clinical focus on peripheral neuropathies and myopathies associated with systemic diseases such as hematological and rheumatological disorders, Hereditary myopathies and neuropathies, and Autoimmune neuromuscular disorders.
How many FSHD patients do you treat?
Added By: ben_adminWhat are your opinions of the phase 1/2 data on del-brax?
Added By: ben_adminHow do you compare the data to Fulcrum's Losmapimod?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
